Abstract:Pancreatic ductal adenocarcinoma (PDAC) is typically diagnosed at an advanced stage, with systemic therapy being the mainstay of treatment. Survival continues to be limited, typically less than 1 year. The PDAC microenvironment is characterized by a paucity of malignant epithelial cells, abundant stroma with predominantly immunosuppressive T cells and myelosuppressive-type macrophages (M2), and hypovascularity. The current treatment options for metastatic PDAC are modified (m)FOLFIRINOX /FOLFIRINOX or nab-paclitaxel and gemcitabine in patients with good performance status (PS) (ECOG 0-1/KPS 70-100%) and gemcitabine with or without a second agent for those with ECOG PS 2-3. New therapies are emerging, and the current guidelines endorse both germline and somatic testing in PDAC to evaluate actionable findings. Important themes related to new therapeutic approaches include DNA damage repair strategies, immunotherapy, targeting the stroma, and cancer-cell metabolism. Targeted therapy alone (outside small genomically defined subsets) or in combination with standard cytotoxic therapy, thus far, has proven disappointing in PDAC; however, novel therapies are evolving with increased integration of genomic profiling along with a better understanding of the tumor microenvironment and immunology. A small but important sub-group of patients have some of these agents available in the clinics for use. Olaparib was recently approved by the US Food and Drug Administration for maintenance therapy in germline BRCA1/2 mutated PDAC following demonstration of survival benefit in a phase 3 trial. Pembrolizumab is approved for patients with defects in mismatch repair/microsatellite instability. PDAC with wild-type KRAS represents a unique subgroup who have enrichment of potentially targetable oncogenic drivers. Small-molecule inhibitors including ERBB inhibitors (e.g., afatinib, MCLA-128), TRK inhibitors (e.g., larotrectinib, entrectinib), ALK/ROS inhibitor (e.g., crizotinib), and BRAF/MEK inhibitors are in development. In a small subset of patients with the KRASG12C mutation, a KRASG12C inhibitor, AMG510, and other agents are being investigated. Major efforts are underway to effectively target the tumor microenvironment and to integrate immunotherapy into the treatment of PDAC, and although thus far the impact has been modest to ineffective, nonetheless, there is optimism that some of the challenges will be overcome.

Advances in Drug Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma

Pancreatic cancer: new approaches to drug therapy

Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities

Advances in biological targeted drugs in pancreatic cancer

Novel Agents for Pancreatic Ductal Adenocarcinoma: Emerging Therapeutics and Future Directions

Diverse and Precision Therapies Open New Horizons for Patients with Advanced Pancreatic Ductal Adenocarcinoma

Targeted Therapies in Pancreatic Cancer: A New Era of Precision Medicine

Recent advances in drug delivery and targeting for the treatment of pancreatic cancer

Systemic Therapy for Metastatic Pancreatic Cancer-Current Landscape and Future Directions

Pancreatic ductal adenocarcinoma cells reshape the immune microenvironment: Molecular mechanisms and therapeutic targets

Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review

Novel Molecular Targets and Mechanisms Involved in the Invasion and Metastasis of Pancreatic Cancer

[Molecular Targeted Therapy Strategy and Clinical Research Progress in Pancreatic Ductal Adenocarcinoma].

A Comprehensive Review of Pancreatic Cancer and Its Therapeutic Challenges.

Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma

Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?

[Advances in Immunotherapy of Pancreatic Ductal Adenocarcinoma].

Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review

Recent Advances in Targeted Drug Delivery for the Treatment of Pancreatic Ductal Adenocarcinoma

Overcoming Drug Resistance in Pancreatic Cancer.